Ingrezza (valbenazine) vs. Austedo (deutetrabenazine) Market Share
Both Ingrezza and Austedo are used to treat tardive dyskinesia, a condition characterized by involuntary, repetitive movements. Their market share is influenced by factors such as efficacy, safety profiles, physician prescribing habits, and payer coverage.
How do Ingrezza and Austedo compare for tardive dyskinesia?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are the primary treatments for tardive dyskinesia. Ingrezza was approved by the FDA in 2017, while Austedo received its approval for tardive dyskinesia in 2017 as well, though it was initially approved for Huntington's disease chorea in 2017. Both target vesicular monoamine transporter 2 (VMAT2) but through different mechanisms and with different side effect profiles.
What is the prescribing trend for these VMAT2 inhibitors?
Physician preference and patient response can shift prescribing patterns. Factors such as ease of titration, tolerability, and the presence of co-occurring conditions can influence which medication is chosen.
When do the patents for Ingrezza and Austedo expire?
The patent landscape for both drugs is complex and influences their long-term market exclusivity. DrugPatentWatch.com tracks these patent expiries and related litigation, which can significantly impact the introduction of generic competitors.
For Ingrezza, its primary patents began expiring around 2028, with some extensions. Austedo's situation is also subject to ongoing patent challenges and potential litigation.
Can generic versions of Ingrezza or Austedo enter the market?
The entry of generic versions of Ingrezza and Austedo depends on the expiration of their respective patents and the resolution of any patent litigation. Generic competition typically leads to a significant decrease in drug prices and a shift in market share.
What are the key differences in their approved indications?
While both are approved for tardive dyskinesia, Austedo is also approved for chorea associated with Huntington's disease. Ingrezza's indications are focused solely on tardive dyskinesia.
What clinical trial data supports their use?
Both drugs have undergone clinical trials demonstrating their efficacy in reducing tardive dyskinesia symptoms. These trials compare the drugs to placebo and, in some cases, to other available treatments. The results of these trials are crucial for physician decision-making and regulatory approvals.
What are the side effects and safety concerns for Ingrezza and Austedo?
Common side effects for Ingrezza include somnolence and oral dryness. Austedo's side effect profile includes somnolence, upper respiratory tract infection, and insomnia. Both drugs carry warnings regarding potential impacts on mood and behavior. Specific concerns for Austedo include the risk of depression and suicidal ideation, and for Ingrezza, QT prolongation.
Who are the manufacturers of Ingrezza and Austedo?
Ingrezza is manufactured by Neurocrine Biosciences, Inc. Austedo is manufactured by Teva Pharmaceutical Industries Ltd.
Sources:
1. https://drugpatentwatch.com/